Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure

  1. Abraham, W.T.
  2. Ponikowski, P.
  3. Brueckmann, M.
  4. Zeller, C.
  5. Macesic, H.
  6. Peil, B.
  7. Brun, M.
  8. Ustyugova, A.
  9. Jamal, W.
  10. Salsali, A.
  11. Lindenfeld, J.
  12. Anker, S.D.
  13. Abraham, W.
  14. Lindenfeld, J.
  15. Welty, F.
  16. Clayton, T.
  17. Greenberg, B.
  18. Konstam, M.
  19. Lees, K.
  20. Palmer, M.
  21. Parhofer, K.
  22. Pedersen, T.
  23. Carson, P.
  24. Freston, J.
  25. Kaplowitz, N.
  26. Lewis, J.
  27. Mann, J.
  28. Petrie, J.
  29. Agostoni, P.
  30. Butler, J.
  31. Desai, A.
  32. Filippatos, G.
  33. Howlett, J.
  34. Wranicz, J.
  35. Mas, J.R.
  36. Cardoso, J.S.
  37. Störk, S.
  38. Show all authors +
Journal:
European Journal of Heart Failure

ISSN: 1879-0844 1388-9842

Year of publication: 2019

Volume: 21

Issue: 7

Pages: 932-942

Type: Article

DOI: 10.1002/EJHF.1486 GOOGLE SCHOLAR lock_openOpen access editor